Vericel to Present at the 38th Annual Canaccord Genuity Growth Conference
July 26 2018 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell
therapies for the sports medicine and severe burn care markets,
today announced that Nick Colangelo, president and CEO, will
present the latest company overview at the 38th Annual Canaccord
Genuity Growth Conference in Boston, Massachusetts on Thursday,
August 9, 2018 at 8:00am Eastern Time.
The presentation will be live webcast at:
http://wsw.com/webcast/canaccord30/vcel/, and may be accessed from
the news and events section of the Vericel website.
About Vericel CorporationVericel is a leader in
advanced cell therapies for the sports medicine and severe burn
care markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. © 2018 Vericel Corporation. All rights reserved.
vcel-corp and vcel-fin
Global Media Contacts:David SchullRusso
Partners LLC+1 212-845-4271 (office)+1 858-717-2310
(mobile)David.schull@russopartnersllc.com
Karen ChaseRusso Partners LLC+1 646-942-5627 (office)+1
917-547-0434 (mobile)Karen.chase@russopartnersllc.com
Investor Contacts:Chad RubinThe Trout
Groupcrubin@troutgroup.com+1 (646) 378-2947
Lee SternThe Trout Grouplstern@troutgroup.com+1 (646)
378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024